Skip to main content

Table 5 Antineoplastic treatment effect on BMD and BMC depending on menopausal status and clinical stage in breast cancer patients (n = 40)

From: Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients

Parameter Premenopause (n = 19) Postmenopause (n = 21)
βa p Confidence Interval
95 %
βa p Confidence Interval
95 %
BMD femoral neck (g/cm2)b All −0.023 <0.001 (−0.032, −0.013) −0.015 0.021 (−0.027, −0.002)
 Clinical stage I, IIA (n = 17)c −0.030 0.004 (−0.047, −0.013) −0.018 0.037 (−0.034, −0.001)
 Clinical stage IIB, IIIA, IIIB (n = 23)c −0.017 0.007 (−0.029, −0.006) −0.0123 0.198 (−0.032, 0.008)
BMD L2-L4 (g/cm2)b All −0.063 <0.001 (−0.086, −0.039) −0.035 0.001 (−0.054, −0.016)
 Clinical stage I, IIA (n = 17)c −0.059 0.006 (−0.095, −0.023) −0.043 <0.001 (−0.059, −0.026)
 Clinical stage IIB, IIIA, IIIB (n = 23)c −0.066 0.003 (−0.102, −0.029) −0.029 0.088 (−0.062, 0.005)
BMC (kg)b All −0.027 0.29 (−0.078, 0.025) −0.036 0.140 (−0.085, 0.013)
 Clinical stage I, IIA (n = 17)c −0.019 0.66 (−0.118, 0.079) −0.005 0.895 (−0.088, 0.078)
 Clinical stage IIB, IIIA, IIIB (n = 23)c −0.032 0.33 (−0.103, 0.038) −0.059 0.078 (−0.126, 0.008)
  1. BMD Bone Mineral Density, BMC Bone Mineral Content
  2. aDetermined by mixed model regression for repeated measures
  3. bMenopausal status and treatment interaction (p ≤ 0.05)
  4. cMenopausal status and clinical stage interaction (p ≤ 0.05)